Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
RESEARCH TOOLSreports
Holding SANA?
Track your performance easily
SANA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $12.00
Previous CloseN/A
Volume118.31M
Average Volume (3M)10.42M
Market Cap
$725.62M
Enterprise Value$872.56M
Total Cash (Recent Filing)$30.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 13, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding223,268,890
10 Day Avg. Volume27,153,954
30 Day Avg. Volume10,421,102
Standard Deviation0.26
R-Squared0.07
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.64
Forecast
1Y Price Target
$11.25Price Target Upside246.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Sana Biotechnology News
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe world's first HIP islet cell transplant was successfully performed without any immunosuppression, demonstrating the potential of Sana's technology.
Innovative TechnologySana announced positive results from the cadaveric pancreatic islet cell program, showcasing that HIP modified islet cells can survive without immunosuppression and produced c-peptide at one month of follow-up.
Market PerformanceSANA shares are soaring +300% after market close after announcing results from the FIH IST of UP421 in a patient with T1D which demonstrated islet cell engraftment, avoidance of immune response and production of insulin.
Bears Say
Financial PerformanceSana reported a Q3 loss of $60MM, indicating financial challenges.
Research And DevelopmentSana is halting further development of SC291 in blood cancers and will seek a partner to advance that portion.
Stock ValuationThe absence of a price target on SANA shares indicates uncertainty in the stock's valuation.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.52 and its highest was $12.00 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $725.62M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 08, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.007.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.25.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 223,268,890 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Among the largest hedge funds holding Sana Biotechnology’s share is Flagship Pioneering Inc.. It holds Sana Biotechnology’s shares valued at 104M.
---
Sana Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.25 (246.15% Upside)
$11.25 (246.15% Upside)
Blogger Sentiment
Neutral
SANA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 25.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 19.2%
Last 30 Days ▲ 140.8%
Last 30 Days ▲ 140.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.89%
12-Months-Change
Fundamentals
Return on Equity
-92.90%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
---
SANA Stock 12 Month Forecast
Average Price Target
$11.25
▲(246.15% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
BioMarin Pharmaceutical
―
Beam Therapeutics
―
Bluebird Bio
―
Best Analysts Covering SANA
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-8.43%
reiterated a buy rating 11 days ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -8.43% per trade.
---